Objective     To identify the efficiency of Oxcarbazepine Oral Suspension monotherapy on the cellular immunity and humoral immunity of children with idiopathic epilepsy.     Methods     A total of 25 children with idiopathic epilepsy (epilepsy group) who were outpatients from March to October 2009 and 21 gender and age matched normal children  (control group) were subjected in this study. Before and in 3 and 6 months after treatment

their venous blood was collected respectively on an empty stomach. An automatic biochemical analyzer (olympusAu640) was employed to detect serum immunoglobulin IgG

IgA and IgM through immune turbidimetry

while the contents of CD3

CD4

CD8 and intercellular adhesion molecule-1 (ICAM-1) were measured with flow cytometry.     Results     Before the oral administration of Oxcarbazepine Oral Suspension

the serum levels of IgA (0.75±0.42 g/L)

IgG (7.74±2.65 g/L)

ICAM-1 (38.07±12.87)

and CD8 (19.61±5.52) in the epilepsy children were significantly higher

while those of CD3 (40.27±9.66) and CD4 (20.63±8.97) were significantly lower than those of the normal control group (P0.05)

whereas there was no significant difference in serum level of IgM between epilepsy children (1.10±0.50 g/L)  and normal control group (P0.05). After the 3-month treatment

the serum levels of IgA (0.29±0.18 g/L)

IgG (6.66±1.84 g/L)

  and CD8(16.27±6.53) were decreased

and that of CD3 (50.55±13.35) were increased. After the 6-month treatment

the serum levels of IgA (0.25±0.13 g/L)

IgG (6.07±1.46 g/L)

CD8(14.22±4.76)

and ICAM-1 (29.83±10.84) were decreased

and that of CD4(26.58±9.76) was increased

with significant differences when compared with those before treatment (P0.05). These values had no significant difference compared with those of normal control group (P0.05)

but there were significant differences when compared with those of normal control (P0.05). There was no significant difference in serum level of IgM among the epilepsy group before or after treatment and normal control group (P0.05). What’s more

no significant difference was found in above-mentioned values between 3 and 6 months after treatment (P0.05).     Conclusion     There are cellular immunity and humoral immunity disorders in children with idiopathic epilepsy before taking antiepileptic drugs. Oxcarbazepine Oral Suspension monotherapy can control as well as improve the immune function in epilepsy children.